Opinion · 3 Nov 2025
Conference abstractPublished 2015
Screening methods to reduce adverse statin effects
University of California, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
W ith more than 25 years of clinical trial data cholesterol-lowering statin drugs are used as the first-line treatment for prevention and treatment of cardiovascular disease. Currently statins are among the most widely prescribed drugs. The occurrence of statin adverse events (AEs) was underestimated in clinical trials. In November 2013 the American Heart Association and the American College of Cardiology published new guidelines that are expected to expand statin use. Gene variations have been identified that modify statin response and increase susceptibility to statin AEs (e.g. SLCO1B1, CoQ2, variants in liver transport genes, variants in drug metabolism). Over the last decade Dr. Golomb’s group investigated statin AE’s, both those reported in patients that were enrolled in the UCSD Statin Effects Study (patient-targeted AE surveillance); and in the UCSD Statin Study (>1000 person randomized double-blind placebo controlled trial). For the former, >5000 patient surveys were submitted, including patient contact information and willingness to be contacted, and these data sets are available for further analysis, with the majority of participants expressing willingness to subjects that reported AEs as well as unaffected controls that previously participated in the UCSD Statin Study. The goal would be to develop predictive models, including questionnaires and pharmacogenomic screening before initiation of statin therapy as well as follow up questionnaires, by which statin therapy/drug choice may be tailored based on the patient’s genetic profile. The hope would be to move toward safer prescribing, to reduce the adverse effect toll from this widely used drug class.
Subjects
Pathology & Lab MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Opinion · 31 Jul 2024
Ongoing Evolution of Cytopathology for Reducing Cancer Mortality through Screening Programs
Research article · 2015
Diagnostic Utility of Reduced Radiation Dose Non-Contrast-Enhanced CT with Iterative Reconstruction for Screening in High-Risk Individuals with Pancreatic Cancer: An Anthropomorphic Phantom Study
Commentary · 8 Mar 2018
Clinical Approach to Statin-Induced Adverse Muscle Events: Challenges and Solutions
Conference abstract · 1 Aug 2016
Adverse reactions to statins: Fact or fantasy
More from this journal
The newest in Journal of Diagnostic Techniques and Biomedical Analysis.
Review article · 9 Aug 2024
Breast Cancer Diagnostics: Molecular Approaches
Opinion · 29 Dec 2023
Molecular Diagnostics: Decoding Disease at the Genetic Level
Opinion · 29 Dec 2023
From Data Streams to Diagnoses: AI's Journey in Healthcare
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Diagnostic Techniques and Biomedical Analysis
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Alice E Zemljic-Harpf”

